ABSTRACT:
People with diabetes need anti-diabetic medications, such as insulin, glucagon-like peptide-1 (GLP-1) and its analogues, to control their blood sugar levels. However, traditional therapies based on hypodermic injections are frequently linked to poor blood glucose management, a lack of patient compliance, and a significant risk of hypoglycaemia. Self-regulated administration, commonly referred to as closed-loop medication delivery techniques, can effectively control the release of drugs Diabetes kinetics in response to the variability in blood glucose levels exhibits great promise. therapy. The advancements in the creation and application of microneedle (MN)-array patches for transdermal. An alternative to the usual hypodermic administration approach is medication delivery. Consequently, the glucose-responsive MN-array. Recently, patches for the treatment of diabetes have garnered more interest. The most recent developments in glucose-responsive MN-array patch systems are outlined in this review. Also covered are their possibilities and obstacles for clinical translation. The ability to administer complicated medications through the skin with ease and comfort is a clinical advantage of microneedles, but they haven't made it into clinical use.
Cite this article:
Kimmi Katoch, Abhilash Kutlehria, Himani Gautam, Kapil Kumar Verma. A Review on Glucose-Responsive Microneedle Patches for Diabetes Treatment. Asian Journal of Pharmacy and Technology. Tech. 2024; 14(1):65-2. doi: 10.52711/2231-5713.2024.00013
Cite(Electronic):
Kimmi Katoch, Abhilash Kutlehria, Himani Gautam, Kapil Kumar Verma. A Review on Glucose-Responsive Microneedle Patches for Diabetes Treatment. Asian Journal of Pharmacy and Technology. Tech. 2024; 14(1):65-2. doi: 10.52711/2231-5713.2024.00013 Available on: https://ajptonline.com/AbstractView.aspx?PID=2024-14-1-13
REFRENCES:
1. Rastogi, V.; Yadav, P. Transdermal drug delivery system: An overview. Asian J. Pharm1. Alkilani, A.Z.; McCrudden, M.T.C.; Donnelly, R.F. Transdermal drug delivery: Innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum. Pharmaceutics. 2015; 7: 438–470
2. Donnelly, A.D.W.R.F.; Singh, T.R.R.; Morrow, D.I.J. Microneedle-Mediated Transdermal and Intradermal Drug Delivery; John Wiley & Sons: Hoboken, NJ, USA, 2012.
3. Han, T.; Das, D.B. Potential of combined ultrasound and microneedles for enhanced transdermal drug permeation: A review. Eur. J. Pharm. Biopharm. 2015; 89: 312–328.
4. Waghule, T.; Singhvi, G.; Dubey, S.K.; Pandey, M.M.; Gupta, G.; Singh, M.; Dua, K. Microneedles: A smart approach and increasing potential for transdermal drug delivery system. Biomed. Pharmacother. 2018; 109: 1249–1258.
5. Prausnitz, M.R.; Langer, R. Transdermal drug delivery. Natl. Inst. Health 2009; 26: 1261–1268.
6. Lee, H.; Song, C.; Baik, S.; Kim, D.; Hyeon, T.; Kim, D. Device-assisted transdermal drug delivery. Adv. Drug Deliv. Rev. 2017; 127: 35–45. 2012; 6: 161–170.
8. Verma, N.K.; Panda, P.; Mishra, J.N.; Vishwakarma, D.K.; Singh, A.P.; Alam, G. Advances and development in transdermal drug delivery system-A Review. Int. J. Adv. Pharm. 2017; 6: 49–62.
9. Goodman, M.P. Are all estrogens created equal? A review of oral vs. transdermal therapy. J. Women’s Health. 2012; 21: 161–169.
10. Pandya, D.; Shinkar, D.; Saudagar, R. Revolutionized Topico-Systemic Era: Transdermal Drug Delivery System. Res. J. Top. Cosmet. Sci. 2015; 6: 66.
11. Mamta, Y.; Satish, N.; Jitendra, B. A Review on Transdermal Patches. The Pharma Research. 2010; 3: 139-149
12. Erdő, F.; Hashimoto, N.; Karvaly, G.; Nakamichi, N.; Kato, Y. Critical evaluation and methodological positioning of the transdermal microdialysis technique. A review. J. Control. Release 2016; 233: 147–161.
12 Gupta, H.; Babu, R. Transdermal Delivery: Product and Patent Update. Recent Pat. Drug Deliv. Formul.2013, 7, 2. 13 Scheuplein, R.J.; Blank, I.H. Permeability of the skin. Physiol. Rev. 1971; 51: 702–747.
14 Seok, J.; Hong, J.Y.; Choi, S.Y.; Park, K.Y.; Kim, B.J. A potential relationship between skin hydration and stamp- type microneedle intradermal hyaluronic acid injection in middle-aged male face. J. Cosmet. Dermatol. 2016; 15: 578–582.
15 Singh, T.; Mcmillan, H.; Mooney, K.; Alkilani, A.; Donnelly, R. Microneedles for drug delivery and monitoring. Microfluid. Devices Biomed. Appl. 2013; 185–230, doi:10.1533/9780857097040.2.185.
16 Donnelly, R.F.; Singh, T.R.R.; Larrañeta, E.; McCrudde, M.T.C. Microneedles for Drug and Vaccine Delivery and Patient Monitoring; John Wiley and Sons, Incorporated: Hoboken, NJ, USA, 2018.
17 Barry, B.W. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur. J. Pharm. Sci. 2001; 14: 101– 114.
18. Lee I.C., He J.S., Tsai M.T., Lin K.C. Fabrication of a novel partially dissolving polymer microneedle patch for transdermal drug delivery. J. Mater. Chem. B. 2015; 3:276–285. doi: 10.1039/C4TB01555J.
19. Gala R.P., Zaman R.U., D’Souza M.J., Zughaier S.M. Novel Whole-Cell Inactivated Neisseria Gonorrhoeae Microparticle Vaccine Formulation in Microneedles for Transdermal Immunization. [(accessed on 4 September 2018)]; 2018 Available online: https://europepmc.org/abstract/ppr/ppr49728
20. Guo L., Chen J., Qiu Y., Zhang S., Xu B., Gao Y. Enhanced transcutaneous immunization via dissolving microneedle array loaded with liposome encapsulated antigen and adjuvant. Int. J. Pharm. 2013; 447:22–30. doi: 10.1016/j.ijpharm.2013.02.006.
21. Damecha D.L. Drug vehicle based approaches on penetration enhancement. International Journal of Pharmacy and Pharmaceutical Sciences. 2009; 1(1): 24-46.
22. Benson A.E.H, Transdermal Drug Delivery: Penetration Enhancement Technique, Current Drug Delivery. 2005; 2: 23- 33.
23. Matteucci M. A compact and disposable transdermal drug delivery system. Microelectronic Engineering. 2008; 85(5-6): 1066-1073.
24. Baert B. A new discrimination criterion for the development of Franze diffusion test for transdermal pharmaceutics. J Pharm Pharmaceutical Sci. 2010; 13(2): 218-230.
25. Guang M., Wang Li. In-vitro and in-vivo characterization of clonidine transdermal patch treatment of attention deficit hyperactivity disorder in children. Biol Pharm. Bull. 2004; 28(2): 305-310.
26. Guo L., Chen J., Qiu Y., Zhang S., Xu B., Gao Y. Enhanced transcutaneous immunization via dissolving microneedle array loaded with liposome encapsulated antigen and adjuvant. Int. J. Pharm. 2013; 447: 22–30. doi: 10.1016/j.ijpharm.2013.02.006.
27. Damecha D.L. Drug vehicle based approaches on penetration enhancement. International Journal of Pharmacy and Pharmaceutical Sciences. 2009; 1(1): 24-46.
28. Benson A.E.H. Transdermal Drug Delivery: Penetration Enhancement Technique. Current Drug Delivery. 2005; 2: 23- 33.
29. Matteucci M. A compact and disposable transdermal drug delivery system. Microelectronic Engineering. 2008; 85(5-6): 1066-1073.
30. Baert B. A new discrimination criterion for the development of Franze diffusion test for transdermal pharmaceutics. J Pharm Pharmaceutical Sci. 2010; 13(2): 218-230.
31. Guang M., Wang Li. In-vitro and in-vivo characterization of clonidine transdermal patch treatment of attention deficit hyperactivity disorder in children. Biol Pharm. Bull. 2004; 28(2): 305-310.